This veterinary study demonstrates that oral NMN supplementation significantly reduces elevated NT-proBNP levels (a cardiac dysfunction biomarker) in dogs with preserved cardiac structure or mild-to-moderate elevation, likely through improved mitochondrial energy metabolism. NMN showed limited efficacy in severe heart disease and required combination with conventional therapy in complex cases. The findings suggest NMN has potential as an adjunctive cardioprotective agent in veterinary practice, though further controlled studies are needed to establish its clinical role.
For your business
Canine NMN data suggests cardioprotective potential via mitochondrial support; may inform adjunctive use in clients with early cardiac biomarker elevation.